Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | BHMT | Q93088 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | ARG1 | P05089 | 1/20 | 0.30 |
| ▸ | ARG2 | P78540 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12421758 | 0.82 | ALDH1A1 (0.42) | ALDH1A1PLA2G4BTSHRKMT2ALMNA | |
| SCHEMBL228309 | 0.80 | — | — | |
| SCHEMBL13227791 | 0.80 | TSHR (0.48) | ALDH1A1PLA2G4BTSHRKMT2ALMNA | |
| Hydrochloric Acid SCHEMBL27635100 | 0.78 | — | — | |
| SCHEMBL310767 | 0.78 | — | — | |
| SCHEMBL10760994 | 0.78 | ALDH1A1 (0.35) | ALDH1A1TSHRKDM4E | |
| SCHEMBL788769 | 0.78 | KMT2A (0.53) | ALDH1A1TSHRKMT2ALMNAHSD17B10 | |
| SCHEMBL12417193 | 0.77 | LMNA (0.50) | ALDH1A1PLA2G4BTSHRKMT2ALMNA | |
| SCHEMBL11862251 | 0.77 | FAAH (0.45) | ALDH1A1PLA2G4BTSHRKMT2ALMNA | |
| SCHEMBL2092810 | 0.76 | ALDH1A1 (0.67) | ALDH1A1TSHRDDAH1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210085781-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2021-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210085781-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | GNE, B3GNT2, KRTCAP2 | ALDH1A1 4018/4885PLA2G4B 4007/4885TSHR 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.